Introduction
Idiopathic generalized epilepsy represents about one third of all epilepsy disorders, and there is increasing evidence that genetic factors play an important role in its development [1] . Considerable progress has been made over recent years in identifying genes that contribute to monogenic forms of epilepsy. The genes identified are components of neuronal signalling, which is composed of voltage-gated ion channels, neurotransmitter receptors, ion channel associated proteins and synaptic proteins [2] .
Most genetic defects detected in idiopathic epilepsy affect the ion channels. Genetic alterations can affect channel function and alter the electrical impulses, modify neuronal excitability and drive networks of neurons into synchronous activity, which can lead to epileptic seizures [3] .
Mutations and genetic variations of GABA-A (Gamma-Aminobutyric acid type A) receptors have been associated with epilepsy. However, only limited types of epilepsy result from such mutations, which are not necessarily the direct cause of epilepsy, but the list of GABA-A receptor mutations associated with epilepsy is expected to grow [4] . The single nucleotide polymorphism in GABA-A receptors' encoding genes provides a new way to identify gene-associated epilepsy [5] .
GABRG2 rs211037 (C588 T) variant may change the sub-units' expression in the GABA-A receptor (the mechanism is unknown), which may affect transcription, mRNA stability and translation efficiency, leading to variability in the receptor composition and in its sensitivity to extrinsic environmental signals [6] . Therefore, we plan to assess the relationship between the genetic variation in the GABARG2 gene (SNP211037) and idiopathic generalized epilepsy, as well as its effect on the predisposition to antiepileptic drug resistance in Egyptian children.
Patients and methods

Participants
Following the approval of the Institutional Ethical Committee of Menoufia University Hospital, and after obtaining written consents from the caregivers of all children to be included in this research, the study was carried out from January through August of 2017 in the Neurology and Genetics Units of the Pediatric Department at Menoufia University Hospitals.
This case-control study was conducted on 210 children who were divided into two groups. Group (I) included 100 children with idiopathic generalised epilepsy (56 females and 44 males), ranging in age from one year to 16 years old. Fifty-four patients were drug-resistant, and 46 patients were drug responders (see Table 1 ). All the patients were identified as having idiopathic generalised epilepsy (the generalised epileptic form, with no etiological factors and no other neurological or neuro-radiologic signs). They also had normal interictal states and had mostly positive generalised spikes in their EEGs (Electroencephalography) [8] .
The patients were presumed to be drug-responsive if they had not suffered from any seizures for a minimum of one year, and they were presumed to be drug-resistant if two tolerated and appropriately chosen and used AEDs had failed to achieve sustained seizure freedom [7] . The anti-epileptic medications were chosen according to the type of seizures and the epilepsy syndrome. Polytherapy was determined by the number of antiepileptic prescriptions that had ever been consumed, not merely at the beginning of the study. Any patients suspected of poor compliance and those with known GABRG2 mutations were excluded.
Group (II) included 110 healthy children served as a control group of matching age and gender (50 females and 60 males) who had no history of epilepsy and febrile convulsions.
Procedure
DNA was extracted from 2 millilitres (ml) of anti-coagulated peripheral blood collected into an EDTA tube by using a DNA extraction kit (thermo whole blood genomic DNA kit). Genomic DNA was amplified using PCR with different forward and reverse primers (Forward 5′-AATCACCTTTTATTCTAATGGTC-3′; Reverse 5′-CAGTGAAGGCAAC TTACTAAGA-3). Thermal cycling was conducted in the thermocycler PTC-100. The initial denaturation was carried out in one cycle at 95°C for 10 min, followed by denaturation by 35 cycles at 95•C for 45 s and annealing by 35 cycles at 55•C for 45 s, then there was an extension by 35 cycles at 72•C for 60 s and a final extension by one cycle at 72•C for15 min. The amplified PCR product of all the samples was resolved in 2% agarose gel detecting a DNA band of 122 bp.
The C588 T polymorphism of the GABRG2 (rs 211 < 037) gene was digested with the APOI restriction enzyme. The reaction mixture was incubated at 37°C in a water bath for five minutes; then, the enzyme was inactivated by heating for 10 min at 65°C. The amplified and digested fragments of DNA were separated on 2% agarose gel with the undigested C allele yielding a single band at 122 bp, whereas the digested T allele generated two bands at 100 bp and 22 bp.
Statistical analysis
IBM SPSS software version 20.0 (SPSS Inc., Chicago, Illinois, United States) was used for statistical analysis. The data were given as the mean ± the standard deviation and also as a range. The categorical : Chi-square test.
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data were analyzed by the chi-square test. Continuous variables were compared using the t-test. The results were valued exploiting a 95 percent confidence interval. A P value < 0.05 was considered to be significant.
Results
This association study of the C558 T polymorphism of the GABARG2 gene with idiopathic generalised epilepsy shows a significant difference in the frequencies of the genotype distribution among cases and controls. The distribution of the CC, CT and TT genotypes was 46.0%, 42.0% and 12.0%, respectively, in the patient group as compared to 61.8%, 36.4% and 1.8% in the control group (P = 0.004). An allele analysis showed a significant increase in the T allele in the patient group (P = 0.002) (see Table 2 ).
Comparing homozygous to heterozygous wild and mutant genotypes of C558 T polymorphism revealed that the mutant genotypes homozygous TT or heterozygous CT were associated with a higher risk of idiopathic generalised epilepsy in children.
Regarding the control of epilepsy symptoms, the analysis of the C558 T polymorphism of the GABRG2 gene showed a significant difference in the frequencies of the genotype distribution among patients, as CC, CT and TT were found to be 29.6%, 48.2% and 22.2% in drugresistant patients as compared to 65.2%, 34.8% and 0.0% in drug responders (P = 0.01) (see Table 3 ).
Correlating the disease prediction and the drug response, the patients carrying a CC genotype and C allele demonstrated a threefold and a fourfold increase in their liability to respond to antiepileptic medications respectively, with a significant increase in the frequency of the T allele among drug-resistant patients [ Table 4 ].
Discussion
Neuronal brain inhibition is largely mediated by the binding of GABA to GABA receptors (GABR). The GABA receptor is the predominant ligand-gated Cl ion channel mediating the fast inhibitory synaptic transmission of the CNS, and is a prime candidate for involvement in epileptogenesis. It comprises a tetramer consisting of α, β, γ subunits. Genes that encode for GABR subunits represent common sites for variations of idiopathic generalised epilepsy susceptibility [9] .
The GABARG2 gene on 5q34 encodes for the γ subunit that is highly expressed in the brain [10] . This subunit plays an important role in the function of post-synaptic transmission of GABA-A receptors [11] . Most of the identified epilepsy and febrile seizure (FS) related mutations in the GABA-A receptors are in the GABARG2 genesuggesting its strong association with the occurrence of seizures [12, 13] . 
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In view of that, on the ground of the functional merit and ongoing suggestions, we tested the probable assumption of one of these genetic variations, the SNP 211037 (Asn196 Asn), at nucleotide position 588. This GABARG2 mutation was alleged to produce nonfunctional γ2 subunits with minimal surface expression [14] .
The authors of this research paper described an association of GABARG2 (rs211037) with the attempt of evolving idiopathic generalised epilepsy of Egyptian children, as there were higher frequencies of the mutant homozygous TT genotype and the T allele of epileptic patients compared to the healthy ones. The g2 subunit was reported to affect the kinetics of GABAA associated channels as well as influencing the synaptic and postsynaptic clustering and maintenance [15] [16] [17] .
The fact that the rs211037 polymorphism plays an important part in the splicing and transcriptional organisation, despite its role of influencing the post-translational folding of protein, has to be researched [18] . Many modifications in GABAA receptor subunit expression and conformation can be entangled in epilepsy development as: mRNA instability; atypical subunit folding; distorted gating of the GABA channel; and defective glycosylation. All these result in changes in receptor assembly, function and trafficking [19] . Moreover, several mutations of this gene result in functional loss of the receptors by a decrease in the level of GABA expression or the speeding up of the deactivation [20] .
The yield of formal literature can disclose the widespread topographical assortment of the frequency of C558 T polymorphism of the GABRG2 gene between diverse ethnicities. Butila et al. [21] showed a significant increase of the mutant TT genotype that reached up to 5.5 times more than CC and CT genotypes of Romanian patients with idiopathic generalised epilepsy (P = 0.0009). Moreover, T allele showed a significant pharmacoresistance to antiepileptic drugs (P = 0.001; OR = 5.29). Indian studies showed diverse results concerning the frequency of C558 T polymorphism among Indian epileptic children. Ponnala et al. [22] reported a higher frequency of the T allele of patients with generalised epilepsy (P = 0.05) with an increase in TT genotype carriers among the recurrent seizure group, compared with well-controlled children (P = 0.06); unlike the results reported by Balan et al. [23] of Indian patients with mesial temporal lobe epilepsy and juvenile myoclonic epilepsy which revealed a significant increase in CC genotype in these patients (P = 0.001) as well as a strong C allele association with epilepsy (P = 0.0006; OR = 1.6). Additionally, there was no significant evidence of drug response to the occurrence of the CC genotype and C allele among patients (P = 0.638, P = 0.718). Similarly, an insignificant association between the C558 T polymorphism and the occurrence of epilepsy and/or pharmacoresistance among Indians was also reported [24] .
The first study of C558 T polymorphism had been done on 77 patients with idiopathic generalised epilepsy and 83 controls from Taiwan uncovered more predominance of the C allele in patients with idiopathic generalized epilepsy (P = 0.002, OR = 3.6) [25] .
A study conducted on 98 unrelated Brazilian patients with juvenile myoclonic epilepsy (JME) revealed no difference of the genotype proportions and allele frequencies for the C558 T polymorphism [26] .
Additionally, the genotype and allele distributions did not show significant deviation among German patients and controls with childhood idiopathic absence epilepsy (P = 0.35 and 0.49) [27] .
Clarifying the linkage between the genetic alteration of the GABAA receptor and the emergence of pharmacoresistance to AEDs, it was found that the main targets of the AEDs were GABA and glutamate neurotransmitters [28] . The GABAA receptor is the molecular target for several common AEDs, such as topiramate, gabapentin, phenobarbital, and benzodiazepines, either directly or through an increase in the GABA concentrations. Consequently, several receptor sites are transformed in the epileptic patients rendering them much less responsive to prescribed medications [29] . Using a rat model with temporal lobe epilepsy, it was found that the drug-resistant rats differed in their GABAA receptor subunit expression from the drug-responsive rats [30] .
In this study, a strong association was realised between the T allele and the drug-resistant group, as 75.8% of patients bearing T allele displayed drug resistance whereas only 24.2% showed evidence of drug response. Because of this, it is understandable that the alliance of GABARG2 C588 T (rs211037) polymorphism with resistant epilepsy in the current study may be attributed to too much glutamate excitation as well as a trigger of drug resistance genes along with modifications in the configuration and functional properties of GABAA receptors that confer on the noticeable loss of drug efficacy.
The conflicting results among research papers investigating the association between the GABAA receptor polymorphism and drug resistance may be explained by phenotype heterogeneity (patient characteristics) and the flexible description of the antiepileptic drug resistance Going along with the frequency of AEDs, polytherapy almost assorted for drug-resistant epilepsy, however, monotherapy was utilized exclusively for drug responsive children, while polytherapy was at hand in both. One-third of patients experienced recurrent convulsions, even with the best possible AED therapy [31] .
Patients who are insensitive to the first two administered prescriptions frequently remain insensitive to all other brands, embracing the new ones, altogether with multiple AED mixtures, signifying their resistance to polytherapy from the start [32] .
Therefore, GABAA receptor genes signify an important class of candidate genes both for epilepsy susceptibility and therapeutic options in epilepsy management. The above noticed topographical variation in the occurrence of GABRG2 C588 T gene polymorphism reflects the genetic diversity of individuals in terms of race and origin of selected populations, and the polygenic multifactorial nature of idiopathic generalized epilepsy as well as the variable effect of known or unknown predisposing environmental factors.
After all, the authors believed that deep sequencing the whole GABAA receptor gene may specify reliable insights and awareness. This should be helped by looking at the receptor functions and conducting further studies on sizeable children cohorts.
Conclusion
GABRG2 C588 T gene polymorphism may contribut to the development of idiopathic generalized epilepsy and pharmacoresistance to antiepileptic prescriptions among Egyptian children. Such data could serve as a basis to personalize epilepsy management and improve the child᾽s quality of life. In the future, we need more studies to continue the promising results of earlier reports and to evaluate the effect of mutations related to GABA-R encoding genes and different types of epileptic seizures.
Study setting
The study was carried out in the Pediatric Neurology and Genetic units at Menoufia university hospitals.
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